share_log

ALLARITY THERAPEUTICS INC | 424B5: Prospectus

SEC announcement ·  Mar 20 12:37
Summary by Moomoo AI
Allarity Therapeutics, Inc. (Allarity) has entered into an At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC, enabling the sale of common stock shares valued up to $947,000. The agreement, dated March 19, 2024, allows Allarity to offer and sell its common stock from time to time through Ascendiant, acting as a sales agent. The shares will be offered utilizing a prospectus supplement dated March 19, 2024, and an accompanying base prospectus dated November 29, 2023. Concurrently, Allarity is facing potential delisting from Nasdaq unless it regains compliance with Nasdaq's listing rules by April 24, 2024. The company's common stock is listed under the symbol 'ALLR.' Allarity has undergone two reverse stock splits, one on March 24, 2023, and another on June 28, 2023, collectively known as the 'Share...Show More
Allarity Therapeutics, Inc. (Allarity) has entered into an At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC, enabling the sale of common stock shares valued up to $947,000. The agreement, dated March 19, 2024, allows Allarity to offer and sell its common stock from time to time through Ascendiant, acting as a sales agent. The shares will be offered utilizing a prospectus supplement dated March 19, 2024, and an accompanying base prospectus dated November 29, 2023. Concurrently, Allarity is facing potential delisting from Nasdaq unless it regains compliance with Nasdaq's listing rules by April 24, 2024. The company's common stock is listed under the symbol 'ALLR.' Allarity has undergone two reverse stock splits, one on March 24, 2023, and another on June 28, 2023, collectively known as the 'Share Consolidations.' As of the prospectus supplement date, Allarity's public float's aggregate market value, held by non-affiliates, was approximately $2.55 million, based on a per-share price of $0.46, the highest closing price within the prior 60 days. The company has not sold any securities pursuant to General Instruction I.B.6 of Form S-3 in the 12 months preceding the prospectus supplement date.

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more